Life science investor adjusts organization to stay on top of its game

Fresh off of promoting several team members to partners, life science venture capital fund Healthcap's founder Björn Odlander talks about new strategy developments and why pension funds and endowments keep returning to the high-risk sector. He is, however, tight-lipped about past performance.

Photo: PR / Healthcap/Dan Coleman AB

Swedish venture capital firm Healthcap specializes in investing in companies that try to find and develop medical solutions to serious diseases such as cancer and genetic diseases.

It's a strategy the firm has had for a long time, and the decision was recently made to expand the team and promote several new partners to advance the efforts.

Five people have boosted the senior team: four of them were promoted from other roles, and the new hire that started in September completes the quintet. Most importantly, Healthcap has promoted Mårten Steen to co-managing partner alongside founder Björn Odlander.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs